aTYR PHARMA (ATYR) Operating Expenses (2014 - 2026)

aTYR PHARMA (ATYR) has reported Operating Expenses for 13 consecutive years, with $10.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 46.43% year-over-year to $10.9 million; the trailing twelve-month figure through Jun 2026 stood at $64.0 million (down 8.57% YoY), and the FY2025 full-year result was $77.8 million, up 14.19% from the prior year.
• Operating Expenses eased to $10.9 million in Q2 2026 per ATYR's latest filing, from $11.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $26.9 million in Q3 2025 and bottomed at $10.9 million in Q2 2026.
• Historically, Operating Expenses has averaged $15.6 million across 5 years, with a median of $15.3 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses surged 112.22% in 2022, then tumbled 46.43% in 2026.
• Over 5 years, Operating Expenses stood at $18.3 million in 2022, then decreased by 12.96% to $16.0 million in 2023, then slipped by 0.87% to $15.8 million in 2024, then declined by 6.47% to $14.8 million in 2025, then declined by 26.46% to $10.9 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $10.9 million, $11.4 million, and $14.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.